Data Source For this analysis, Avalere used commercial and Managed Medicaid claims data from Inovalons proprietary Medical Outcomes Research for Effectiveness and Economics (MORE 2 ) Registry, accessed by Avalere via an Agreement with Inovalon, Inc
Footnotes Disclosure statement: The authors have nothing to disclose Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication
Biomarker improvements: Significant reductions in systolic blood pressure, fasting triglycerides, and hepatic fat content
Wright commented that [t]he precise mechanism of these improvements remains speculative but does not appear to be purely related to weight loss. Indeed, he added, much of the benefit in these patients with heart failure seemed to be manifest prior to any substantial weight loss, strongly suggesting that the GLP-1 receptor agonist led to improvements in the metabolic syndrome and the heart failure syndrome, independent and perhaps additive to those expected from weight loss. Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, not involved in this research, welcomed its findings
I., Hanley, M
